Pfizer’s multi-year lows reflect headwinds, lack of catalysts, and fading appeal to both growth and defensive investors. Read ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Recursion Pharmaceuticals (RXRX – Research ...

Discover top BBB dividend dogs with projected average net gains of 43.38% by 2026. Explore investment picks like Pfizer & ...